Philipp Emanuel Hartrampf
Arzt
Geboren:
19XX
Hat mitgewirkt an:
-
Evaluation der PET-Tracer [\(^1\)\(^8\)F]FDG, [\(^1\)\(^8\)F]Cholin und [\(^6\)\(^8\)Ga]PSMA I&T zur nicht-invasiven Charakterisierung von Prostatakarzinomzellen und des Ansprechens auf eine...
-
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T during long-term follow-up
-
Radiopharmaceuticals for treatment of adrenocortical carcinoma
-
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T